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SUMMARY
Organising pneumonia (OP) is a form of interstitial
pneumonia characterised by inflammation and scarring
leading to obstruction within the small airways and
alveoli. Practice guidelines recommend treatment of
moderate to severe OP with glucocorticoids; however,
there have been cases of steroid-resistant OP successfully
treated with rituximab. We describe a case of a woman
in her 20s with rheumatoid arthritis who presented
with pleuritic chest pain, haemoptysis and dyspnoea
on exertion and was diagnosed with OP after multiple
radiographic images and biopsies. The patient failed
numerous treatment regimens, including corticosteroids,
antibiotics and mycophenolate, but was successfully
treated with rituximab. This case highlights the
importance of identifying new therapeutic agents that
will minimise the use of glucocorticoids in the treatment
of OP.

BACKGROUND
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Organising pneumonia (OP) is a form of interstitial pneumonia characterised by inflammation and
scarring that leads to obstruction within the small
airways and alveoli.1 OP usually affects individuals in the fifth or sixth decade of life and typically
manifests as acute symptoms of non-
productive
cough, dyspnoea, fever, malaise and weight loss that
generally persists for weeks to months.2 The underlying cause of the condition is unknown however it
is thought to be a consequence of epithelial injury
to alveoli leading to protein leakage, fibroblast
recruitment and subsequent fibrin formation within
the lumen of alveoli.3–5 Since there have been few
randomised controlled trials, treatment is based
on practice guidelines. Current practice guidelines
recommend no treatment for mild cases of OP and
recommend glucocorticoids for moderate to severe
cases of OP.6–9 In patients with steroid-
resistant
disease, cytotoxic agents such as cyclophosphamide along with macrolides are recommended,
however, there have been reported cases of steroid-
resistant OP successfully treated with rituximab.4
Here, we illustrate a case of OP in a woman in her
20s presenting as haemoptysis and multiple lung
nodules on imaging that was successfully treated
with rituximab after minimal improvement with
combination of glucocorticoids and antibiotics.

CASE PRESENTATION

A young woman in her 20s with a history of juvenile idiopathic arthritis (JIA) diagnosed at 14
presented to the rheumatology clinic with haemoptysis that progressively worsened over a 1-
week

period. The patient’s diagnosis of JIA was made at
14 when she presented with polyarticular joint pain
primarily affecting her right shoulder, right elbow,
right knee, bilateral wrists and bilateral hands. The
patient initially believed that the arthritis was due
to overuse injuries because she was very active in
soccer; however, when she began to develop synovitis and joint swelling, the patient was referred to
a rheumatologist. The patient’s laboratory workup
revealed a negative rheumatoid factor and antinuclear antibodies with high titre positive anti-cyclic
citrullinated peptide antibody >250 units/mL
(reference range less than 20 units/mL). She was
initially treated with methotrexate 20 mg subcutaneously weekly and etanercept 50 mg subcutaneously once weekly. The patient’s symptoms
drastically improved on this regimen; however, the
patient missed her follow-up appointments and had
intermittent care up until the current visit. On her
current presentation, she endorsed pleuritic chest
pain and mild dyspnoea on exertion that had been
present since onset of haemoptysis. In the past, the
patient was diagnosed with pulmonary nodules in
bilateral lung fields which spontaneously resolved
dating back 3 years prior to current presentation.
Her vital signs showed a temperature of 37.3°C,
a blood pressure 138/88 mmHg, a pulse oximetry
saturation of 98% on room air and a respiratory
rate of 18 breaths per minute. Her physical examination was notable for rhonchus breath sounds to
bilateral lower lung fields, synovial thickening of
metacarpophalangeal joint two and three of the left
hand, and tenderness to proximal interphalangeal
joints three and four bilaterally.

INVESTIGATIONS
The patient’s laboratory findings are shown in table 1.
Given the patient’s symptoms, she had a chest X-ray
performed which showed left perihilar opacities
(figure 1), which warranted further investigation with
a CT chest. CT of the chest revealed multiple bilateral basal lung nodules measuring up to 4.0 cm and
a 1.2 cm consolidation noted at the lingula with few
areas of ground glass opacities (figure 2). The patient
had a transthoracic biopsy performed which revealed
granulomatous inflammation with caseous necrosis
with silver and mucin stains negative for fungi or
acid-
fast bacilli. Furthermore, immunoperoxidase
staining for tuberculosis was negative. At that time, the
patient was diagnosed with a granulomatous infection
despite being unable to identify any specific organisms
however when patient had repeat imaging performed
2 months later, the nodules had resolved (figure 3). In
between visits, the patient had only been treated with
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Table 1

Laboratory findings

Parameter

Finding

Reference range

WCCC

12.5x109/L

<10.9 103 cells/ µL

Haemoglobin

89 g/L

108–147 g/L

Platelet

613 x109/L

30–999 103 cells/µL

Creatinine

45.75 µmol/L

<91.5 µmol/L

Sedimentation rate

87 mm/hour

0–32 mm/hour

C reactive protein

12.4 mg/L

<10.0 mg/L

Antinuclear antibody

1:320

<1:80

C-ANCA

<1:20

<1:20

P-ANCA

1:2560

<1:20

Anti-myeloperoxidase antibody

<9.0 IU/mL

0–9 IU/mL

Anti-proteinase-3 antibody

<3.5 IU/mL

0–3.5 IU/mL

Rheumatoid factor

3 UI/dL

<20 UI/dL

Anti-citrullinated protein antibody

>250 units

<20

Figure 2 CT chest without contrast demonstrating multiple bilateral
lung nodules measuring up to 4.0 cm and a 1.2 cm consolidation noted
at the lingula with a few areas of ground glass opacities.

WCC, white cell count.

methotrexate 20 mg orally weekly for baseline rheumatoid arthritis.
Over the following few months her symptoms recurred with new
pulmonary nodules on imaging (figure 4). During these episodes,
the patient had a bronchoscopy with bronchoalveolar lavage which
revealed negative cultures. She was treated with prednisone 40 mg
with decreasing doses over weeks, which did improve the symptoms
briefly however the symptoms of haemoptysis and pleuritic chest
pain began to recur more frequently and persist despite treatment.
Ultimately, the patient underwent an open lung biopsy with results
of pathology revealing very focal OP in which polypoid plugs of
organising fibroblasts and myofibroblasts are situated within the
lumens of distal airspaces. These findings were accompanied by a
variably conspicuous chronic interstitial pneumonia in which alveolar septae and peri-bronchial interstitium are expanded by an infiltrate of predominantly mononuclear cells including lymphocytes
and plasma cells. The foci of subpleural interstitial pneumonia are
associated with foamy alveolar macrophages. There was no evidence
of necrotising granulomatous inflammation identified (figures 5–7).

DIFFERENTIAL DIAGNOSIS

The patient presented with haemoptysis, pleuritic chest pain
and radiographic imaging that revealed lung masses in the
background of a diagnosis of rheumatoid arthritis. Given her
symptoms, the list of differentials is vast, with the highest suspicion being for malignancy, infection, vasculitis, rheumatoid
arthritis-associated interstitial lung disease (RA-ILD), rheumatoid nodules and OP. Our initial biopsy revealed no evidence of
fungal or mycobacterial infection which ruled out infection as
the cause of her symptoms. Similarly, there was no evidence of
malignant cells on bronchoalveolar lavage or biopsy and given

Figure 1
2

Chest X-Ray showing left perihilar opacities.

Figure 3 CT chest without contrast with improvement of bilateral
basal lung nodules however persistent lingula consolidation.
the spontaneous resolution of the masses, malignancy was ruled
out. The diagnosis of vasculitis was entertained especially given
the high titre P-ANCA 1:2560, however, myeloperoxidase and
proteinase-3 were negative, and the patient never presented with
constitutional symptoms. The presence of P-ANCA, regardless of
the titre, without the appropriate clinical context and MPO antibody positivity is non-specific and can be seen in other rheumatological and non-rheumatological conditions. The most common
histopathological subtype of RA-ILD is usual interstitial pneumonia (UIP).10 The risk factors for RA-ILD include male gender,
older age, cigarette smoking and more severe and active RA.11
The typical findings on high-resolution CT include subpleural,
bibasilar reticular opacities associated with honeycomb changes
and traction bronchiectasis. The histopathology will show areas
of normal lung alternating with interstitial inflammation, fibroblast foci, and honeycomb changes.12 Our patient did not meet
any of the abovementioned risk factors except for more severe
RA and did not have characteristic imaging or histopathologic
findings to meet criteria for the diagnosis of UIP.

Figure 4 CT chest without contrast with multiple basilar nodules with
the largest measuring 6.3 cm, worse than previous CT chest.
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without recurrence of haemoptysis and pleuritic chest pain.
Due to being on a prolonged course of prednisone, she began
to have glucocorticoid toxicity including a 20 lb weight gain,
non-alcoholic fatty liver disease and secondary diabetes mellitus.
At that point in time, due to her persistent symptoms, failure
of treatment with steroids and anecdotal cases in the literature,
the patient was started on rituximab 1000 mg for two doses,
followed by an additional dose 6 months later as per rheumatoid
arthritis protocol.4

OUTCOME AND FOLLOW-UP

The patient has been in remission for 8 months without any new
episodes of haemoptysis, chest pain or radiologic findings on
imaging (figure 8). She is no longer taking steroids or immunosuppressive agents.
Figure 5 H&E biopsy pleura demonstrating foamy alveolar
macrophages within the subpleural interstitium.
Lastly, rheumatoid lung nodules are specific to the diagnosis of
RA and are typically asymptomatic. These nodules can be single
or multiple and are typically located in subpleural areas or interlobular septa and can range from millimetres to several centimetres in size.13 14 These nodules can cavitate and rupture, resulting
in infection, haemoptysis and effusions. The histopathology of
these nodules demonstrates central necrosis, palisading epithelioid cell, mononuclear cell infiltrate and vasculitis.15 16 Although
this was one of the differentials in our patient, histopathology
did not correlate with the expected findings. Based on the biopsy
results, the recurrent and spontaneous nature of the pulmonary
nodules, and the patient’s history of rheumatoid arthritis, a diagnosis of OP was made.

DISCUSSION

In this discussion, we will focus on the current practice guidelines and diagnostic criteria of OP, highlight cases of OP treated
with rituximab from the literature, and explain our rationale for
deviating from standard of therapy.
OP is a diagnosis of exclusion and should be suspected given the
appropriate clinical context and characteristic symptoms. Diagnostic
imaging such as CT, chest X-ray and lung biopsy with histopathological findings of intra-alveolar buds of granulation tissue, consisting
of intermixed myofibroblasts and connective tissue with or without

TREATMENT

Given the diagnosis of OP, the patient was started on a course
of prednisone 60 mg daily with a decreasing taper dose over the
subsequent weeks along with clarithromycin 250 mg two times
per day for several months. During this time, mycophenolate 2.0
g daily was added to the corticosteroids, however, the patient
could not have the dose decreased below prednisone 20 mg daily

Figure 7 A ×40 H&E wedge biopsy left lower lung demonstrating
polypoid plugs of organising fibroblasts and myofibroblasts situated
within the lumens of distal airspace with associated lymphocytes and
plasma cells within alveolar septae and peribronchial interstitium.

Figure 6 A ×10 H&E wedge biopsy left lower lung demonstrating
polypoid plugs of organising fibroblasts and myofibroblasts situated
within the lumens of distal airspace with associated lymphocytes and
plasma cells within alveolar septae and peribronchial interstitium.
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Figure 8 CXR with improvement of perihilar opacities, no new or
worsening infiltrates noted.
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bronchial intraluminal polyps help confirm the diagnosis.3 4 17 The
current practice guidelines base treatment on the severity of the
presentation. Patients with mild symptoms and minimal radiographic changes are likely to have resolution of symptoms without
pharmacological intervention, however, if symptoms worsen at
any point throughout the clinical course, treatment should be initiated.9 Patients with mild to moderate disease can be treated with
clarithromycin as per case reports, however, macrolide therapy has
been shown to be less effective than glucocorticoid therapy based on
long-term retrospective studies.6–9 For patients with worsening and
severe symptoms, glucocorticoid therapy is standard of care. The
initial dose is typically 0.75–1.0 mg/kg per day per ideal body weight
as per British Thoracic Society guidelines.12 The initial dose should
be continued for 1–2 months and if the symptoms remain stable or
improve, a steroids should be decreased over the next 4–6 weeks
and the discontinuation of steroids should be achieved by 6 months.
Unfortunately, relapses are common in OP and many patients will
fail to respond to corticosteroid therapy. In these cases, there are no
specific guidelines on the correct approach to treatment. Anecdotal
evidence suggests the use of cyclophosphamide or cyclosporine in
the treatment of OP when steroid resistant occurs however there
have been cases of successful treatment with rituximab.4 18 19
In reviewing the literature, we identified one article that discussed
the successful treatment of OP with Rituximab. Shitenberg et al
reported four patients with biopsy proven OP who were successfully
treated with Rituximab. The patients that he identified were Caucasian, between 54 and 82 years of age, and did not report underlying
connective tissue disease. Each of his patients had been on high dose
corticosteroids without resolution of symptoms. With the addition
of rituximab at 375 mg/BSA, one of the patients reached complete
remission without the addition of any other cytotoxic or corticosteroid therapy. The remaining three patients had to continue steroid
treatment to remain in remission however the steroids were maintained at much lower doses.4
The clinical presentation of our patient was atypical as she had
haemoptysis along with chest pain as her initial symptomology. The
literature reports that haemoptysis is an exceedingly rare presentation of OP and typical age of onset is between the fifth and sixth
decade of life.12 20 21 Our patient presumably had radiographic findings in late adolescence before her 20s, however, she did not have a
formal diagnosis until years later following multiple imaging studies
and biopsies. The heterogeneity of OP highlights the importance of
a very thorough clinical and diagnostic investigation to confirm the
diagnosis. Our patient was treated with a combination of antibiotics
and glucocorticoids for several months without complete resolution of symptoms. On the contrary, her symptoms began to recur
more frequently and were more persistent. Despite the utilisation
of steroid sparing agents such as mycophenolate, we were unable
to decrease her prednisone below 20 mg daily and as a result, she
developed significant side effects from steroid use. Previously, she
failed multiple treatment regimens for rheumatoid arthritis including
methotrexate and etanercept; thus, we did not feel that her condition would significantly improve on these agents despite literature suggesting appropriate clinical response to these agents in OP
secondary to rheumatoid arthritis.22 Throughout her clinical course,
her rheumatoid arthritis was intermittently flaring, and we wanted to
use an agent that would target both diseases. Our suspicion was that
if we controlled her underlying connective tissue disease, we could
alleviate the symptoms of OP. Despite the scarcity of cases in the
literature regarding treatment of OP with rituximab, we felt that our
patient would benefit from this therapeutic avenue. As predicted, the
patient was successfully treated with rituximab. Of note, it is essential
to mention that there have been reported cases of rituximab-induced
OP.23 24 The exact mechanism is not well established; however, risk
4

Patient’s perspective
As a mother, I was initially reluctant to have invasive diagnostic
testing or start aggressive treatment. After some time, my
condition began to interfere with my activities of daily living
which prompted me to agree to further testing and treatment.
After successfully being treated, I am considering a career in
medicine.

Learning points
► Pulmonary nodules in the setting of rheumatoid arthritis give

rise to a vast differential diagnosis.

► P-ANCA, in the absence of myeloperoxidase antibodies, is

non-specific for vasculitis.

► Although commonly seen in the fifth and sixth decade of life,

organising pneumonia (OP) can be seen in younger patients
with an underlying connective tissue disease.
► Patients with glucocorticoid-resistant OP can be successfully
treated with rituximab in the appropriate clinical setting.

factors include recurrent exposure to rituximab and concurrent
rituximab and granulocyte colony-stimulating factor.25 We believe
this case highlights the importance of further studies on the role of
CD-20 inhibition in the treatment of OP.
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